cyclopharm

27 November 2024

cyclomedica
technegas

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

CYCLOPHARM RECEIVES FIRST PURCHASE ORDERS FROM TWO UNITED STATES VETERANS HEALTH ADMINISTRATION HOSPITALS

Cyclopharm Limited (ASX: CYC) is pleased to announce that it has received purchase orders from two United States Veterans Health Administration (VA) Hospitals. These purchase orders received today for an initial five-year term, apply to the installation and annual charges associated with the Technegas System.

Today's news is linked to Cyclopharm's 3 October 2024 announcement that the company had been awarded an Interim Agreement (IA) to supply the Veterans Health Administration (VA), the largest integrated US Government health care system in the United States (US), for the pharmaceutical and consumable components of Technegas.

Cyclopharm CEO James McBrayer said, "The purchase orders received today for the Technegas Systems, combined with the national agreement awarded last month for the patient consumables, will allow for the first installations of Technegas within the VA system during the first few weeks of 2025. Once installed, Technegas revenues will be generated immediately as our technology will be replacing existing nuclear medicine products".

Technegas' ability to provide highly accurate functional ventilation images is a key diagnostic aid for conditions such as chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis, a condition affecting veterans impacted by toxic exposures during active service. By improving diagnostic accuracy, Technegas will aid in the VA's effective treatment and management of lung disease in affected veterans, enhancing care under the PACT Act[1].

Mr McBrayer concluded by stating, "We are very pleased that US veterans will soon have access to our Technegas technology. More broadly, these initial commercial agreements will also serve as a template for the remaining 118 nuclear medicine departments located in VA hospitals".

ENDS -
This ASX announcement was approved and authorised for release by James McBrayer, Managing Director and CEO.

[1] PACT Act – 1.Expands and extends eligibility for VA health care for Veterans with toxic exposures and Veterans of the Vietnam era, Gulf War era, and Post-9/11 era. 2. Expands eligibility for benefits for Veterans exposed to toxic substances (https://www.va.gov/files/2023-08/PACT%20Act%20Overview%20101_v11.7.22%20%281%29.pdf)

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

Cyclopharm Limited
Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®
The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

In the United States the Technegas approved indication for use for use is:
TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older is for the visualization of pulmonary ventilation and the evaluation of pulmonary embolism when paired with perfusion imaging.